Ionis Pharmaceuticals in the NEWS Today, Sep. 2, 2025, Ionis Pharmaceuticals (IONS) announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In the studies, olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% and a highly statistically significant reduction in acute . . . This content …

Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The presentations will be webcast, providing company updates for investors.   Investor Conference Presentations  Citi's 2025 Biopharma Back to School Conference:  Alnylam management will present an overview of the company on Wednesday, September 3, 2025. Morgan Stanley 23rd Annual Global Healthcare Conference: A presentation is also scheduled for Monday, September . …

Approved COVID-19 Vaccines As of late August 2025, the U.S. Food and Drug Administration (FDA) has approved updated versions of the COVID-19 vaccines from Pfizer, Moderna and Novavax.  These updated shots are intended to better protect against currently circulating variants. The 2024–2025 formulations of the following vaccines are approved for certain groups: Pfizer (

BioArtic AB & Novartis Sign Agreement Stockholm, Sweden, August 26, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG (

One bad market day or more can help investors make it a good biotech market day. On the bad market days, many star firms become way undervalued for no reason whatsoever. Instead of selling these stocks Prohost's motto is to buy more. On Another Topic Prohost decided to buy NTLA. Recently this company's stocks started moving up, including yesterday, a bad market day.  We selected …

Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced  that the U.S. FDA has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory . . . This content is for paid …

Rhythm Pharmaceuticals in the NEWS Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. FDA has accepted for filing the company’s supplemental New Drug Application (sNDA) for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA

Precigen in the NEWS Precigen (PGEN) announced that the United States (FDA) has approved the product  PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP. Precigen completed submission of the rolling Biologics License Application (BLA) in December 2024 . . . This content is for paid subscribers. Please click here …

Insmed Incorporated Today, investors must have realized the upward movement prices of the Viking Therapeutics (VKTX) and Intellia Therapeutics (NTLA . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Boehringer Ingelheim The following is not for investors but for people who love pets and want them to be healthy and live longer. Those who care about animals should know what’s going on in the highly regarded veterinary research and practice, and the next generation of biomedical researchers. Recently, a posted text informed that Boehringer Ingelheim has celebrated the next generation of biomedical researchers at …

Akero Therapeutics Akero Therapeutics (AKRO) reported its Q22025 financial results for the period ending June 30, 2025 as well as providing a business update. The report was published from the 96-Week Phase 2b SYMMETRY trial published in the New England Journal of Medicine. Three presentations highlighted data demonstrating statistically significant reversal of MASH compensated cirrhosis, and the anti-fibrotic activity . . . This content is …

Gilead Sciences Reached Prohost Biotech's Target Gilead Sciences (GILD) reached our target of $120 today. Some investors will sell some and keep some and other investors will sell all the stocks they have. We will keep our stocks as we are increasing the target. Yesterday was Gilead's announcement of its second Quarter 2025 financials. The following is what . . . This content is for …

Praxis Precision Medicines in the NEWS  On Aug. 04, 2025, the biopharmaceutical company Praxis Precision Medicines (PRAX), translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance provided a corporate update and reported financial results for the second quarter 2025. From Praxis Precision Medicines “In the second quarter, we continued to make remarkable progress across our portfolio …

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress The Financial Results and More  Today, July 31, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of . . . This content …

AstraZeneca Imfinzi Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first and only perioperative immunotherapy-based regimen in this setting AstraZeneca’s (AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment . . . This content is for …

Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators. On July 25, 2025,  Klotho Neurosciences, Inc. (KLTO) announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and also  longevity.  In addition to its core . . . This content is for paid subscribers. Please click here to subscribe …

GSK in the NEWS Today, GSK plc (GSK) announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). From GSK Court Horncastle, Senior Vice President at GSK, said,  “Too many people . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Eli Lilly Acquired Verve Therapeutics Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (

AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26.  Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline …

AstraZeneca in the NEWS Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company’s largest single Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% investment in a facility to date AstraZeneca (AZN) announces $50 billions of investment in the . . . This content is …